NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Ginkgo & OpenAI Slash Protein Synthesis Costs by 40%

Ginkgo Bioworks teams up with OpenAI to cut cell-free protein synthesis costs by 40% using AI and cloud lab automation.

Ginkgo & OpenAI Slash Protein Synthesis Costs by 40%
Credit: Chona Kasinger/Bloomberg via Getty Images
Already have an account? Sign in.
Featured/ 02/05/2026 · 3:28 PM
DNA
/ Don’t stop at just one post.

Related↓

Ginkgo Bioworks and Bayer Extend Partnership to Advance Sustainable Agriculture
10/31/2025 · 11:15 AM

Ginkgo Bioworks and Bayer Extend Partnership to Advance Sustainable Agriculture

Ginkgo Bioworks extends its multi-year collaboration with Bayer to develop next-generation biological products for agriculture, focusing on nitrogen fixation and sustainable farming.

/ Subscriber only
/ Read more

Feed↓

AbbVie and Genmab Report Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Relapsed/Refractory DLBCL
06/30/2026 · 4:58 AM

AbbVie and Genmab Report Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Relapsed/Refractory DLBCL

New drug combo helps lymphoma patients live longer without worsening disease, cutting risk by ~60%—without chemotherapy.

/ Subscriber only
Abivax Shares Surge as Obefazimod Delivers Strong Phase 3 Results in Difficult-to-Treat Ulcerative Colitis
Featured/ 06/29/2026 · 5:34 PM

Abivax Shares Surge as Obefazimod Delivers Strong Phase 3 Results in Difficult-to-Treat Ulcerative Colitis

Abivax advances toward Q4 2026 NDA filing with encouraging remission and safety results.

/ Subscriber only
FDA Clears Gain Therapeutics’ GT-02287 for Phase 2 Parkinson’s Trials
06/29/2026 · 5:06 PM

FDA Clears Gain Therapeutics’ GT-02287 for Phase 2 Parkinson’s Trials

Phase 2 trials in early Parkinson’s to start Q3 2026 in U.S. & Europe after strong Phase 1 biomarker and safety data.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe